Tag: Glenmark Pharmaceuticals
Glenmark Pharmaceuticals secures FDA approval for generic version of Otezla Tablets
Glenmark Pharmaceuticals Ltd. has successfully secured the final approval from the United States Food & Drug Administration (U.S. FDA) for its Apremilast Tablets in 10 ... Read More
Ichnos Sciences strikes exclusive global deal with Astria Therapeutics for OX40 antibody portfolio
Ichnos Sciences, a prominent clinical-stage biotechnology firm specializing in pioneering multispecific antibodies for oncology and under the ownership of Glenmark Pharmaceuticals, has announced a momentous ... Read More
Glenmark Pharma to sell 75% stake in Glenmark Life Sciences to Nirma Limited
Glenmark Pharmaceuticals (Glenmark Pharma), a research-led global pharmaceutical player, has inked a deal with Nirma Limited to divest a substantial 75% stake in its offshoot, ... Read More
Glenmark Pharmaceuticals gets FDA approval for generic Protopic Ointment
Glenmark Pharmaceuticals Ltd., a global leader in pharmaceutical research, has secured the final nod from the U.S. Food & Drug Administration (U.S. FDA) for its ... Read More
Glenmark Pharmaceuticals gets FDA final approval for Compazine generic
Glenmark Pharmaceuticals has bagged final approval for Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg from the US Food & Drug Administration (FDA). The ... Read More
Glenmark Pharmaceuticals set to begin clinical trial of GRC 54276 in US
Glenmark Pharmaceuticals, through its subsidiary Glenmark Specialty, is set to begin a first-in-human, phase 1/2 clinical study of GRC 54276 in the US for the ... Read More
Glenmark Pharmaceuticals gets FDA second tentative approval for Saxagliptin Tablets
Glenmark Pharmaceuticals Inc., USA has secured a second tentative approval from the United States Food and Drug Administration (FDA) for Saxagliptin Tablets, 2.5 mg and ... Read More
Glenmark Pharmaceuticals to sell certain dermatology brands to Eris Lifesciences
Glenmark Pharmaceuticals has agreed to sell certain brands from its dermatology segment in India and Nepal to Eris Oaknet Healthcare, a fully-owned subsidiary of Eris ... Read More
Glenmark Pharmaceuticals rolls out heart failure treatment Sacu V in India
Glenmark Pharmaceuticals said that it has rolled out the sacubitril + valsartan tablets for the treatment of heart failure in India under the brand name ... Read More
Glenmark Pharmaceuticals launches Bumex Injection generic in US
Glenmark Pharmaceuticals said that its US-based subsidiary has launched Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) SingleDose Vials and 2.5 mg/10 mL (0.25 mg/mL) ... Read More